These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 27817251)

  • 21. Assessment of the efficacy of a last-generation polyvalent immunoglobulin in the treatment of idiopathic thrombocytopenic purpura.
    Pacetti P; Garau D; Caramatti C; Mangoni L; Zamboni V; Canova N; Rizzoli V
    Curr Med Res Opin; 1997; 13(9):517-27. PubMed ID: 9169254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life.
    Bussel JB; Eldor A; Kelton JG; Varon D; Brenner B; Gillis S; Angiolillo A; Kulkarni R; Abshire TC; Kelleher J;
    Thromb Haemost; 2004 Apr; 91(4):771-8. PubMed ID: 15045139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recurrent immune thrombocytopenic purpura in children.
    Jayabose S; Levendoglu-Tugal O; Ozkaynak MF; Sandoval C
    Pediatr Hematol Oncol; 2006 Dec; 23(8):677-82. PubMed ID: 17065144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
    Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical statistics and effectiveness of different treatments of idiopathic thrombocytopenic purpura].
    Kovaleva LG; Pustovaia EI; Safonova TI; Riadnenko AA; Kolosova EN
    Ter Arkh; 2011; 83(4):60-5. PubMed ID: 21675277
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of a nanofiltered liquid intravenous immunoglobulin product in patients with primary immunodeficiency and idiopathic thrombocytopenic purpura.
    van der Meer JW; van Beem RT; Robak T; Deptala A; Strengers PF
    Vox Sang; 2011 Aug; 101(2):138-46. PubMed ID: 21749402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Current treatment of primary immune thrombocytopenia].
    Lozano ML; Vicente V
    Med Clin (Barc); 2014 May; 142(9):399-405. PubMed ID: 23809409
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Idiopathic thrombocytopenic purpura: a 10-year natural history study at the childrens hospital of alabama.
    Watts RG
    Clin Pediatr (Phila); 2004 Oct; 43(8):691-702. PubMed ID: 15494875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune thrombocytopenic purpura in adults in the last 10 years: single-centre experience.
    Pavkovic M; Trpkovska-Terzieva S; Sotirova T; Latifi A; Cevreska L; Stojanovic A
    Prilozi; 2012; 33(1):121-33. PubMed ID: 22952099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of adult idiopathic thrombocytopenic purpura.
    Nakhoul IN; Kozuch P; Varma M
    Clin Adv Hematol Oncol; 2006 Feb; 4(2):136-44, 153. PubMed ID: 16728922
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overview of 321 patients with idiopathic thrombocytopenic purpura. Retrospective analysis of the clinical features and response to therapy.
    Pamuk GE; Pamuk ON; Başlar Z; Ongören S; Soysal T; Ferhanoğlu B; Aydin Y; Ulkü B; Aktuğlu G; Akman N
    Ann Hematol; 2002 Aug; 81(8):436-40. PubMed ID: 12224000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Appropriate hospital management of adult immune thrombocytopenic purpura patients in major Italian institutions in 2000-2002: a retrospective analysis.
    Cirasino L; Robino AM; Cattaneo M; Pioltelli PE; Pogliani EM; Terranova L; Morra E; Colombo P; Palmieri GA; Piscitelli P
    Blood Coagul Fibrinolysis; 2010 Jan; 21(1):77-84. PubMed ID: 19858712
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical course of children with immune thrombocytopenic purpura treated with intravenous immunoglobulin G or megadose methylprednisolone or observed without therapy.
    Duru F; Fisgin T; Yarali N; Kara A
    Pediatr Hematol Oncol; 2002 Jun; 19(4):219-25. PubMed ID: 12051587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pretreatment with standard-dose intravenous methylprednisolone does not improve outcomes in newly diagnosed immune thrombocytopenia (ITP).
    Essilini A; Comont T; Germain J; Brun N; Dingremont C; Castel B; Arista S; Madaule S; Sailler L; Lapeyre-Mestre M; Beyne-Rauzy O; Godeau B; Adoue D; Moulis G;
    Eur J Haematol; 2018 May; 100(5):412-418. PubMed ID: 29360249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of immune thrombocytopenic purpura in Pediatrics. Therapeutic efficacy of a regional intravenous immunoglobulin G].
    Buteler C; Colombo H; Gabosi G; Manfredi MJ; Montero S; Pasquali MA; Rougier C; Sisti AM
    Medicina (B Aires); 2001; 61(5 Pt 1):522-8. PubMed ID: 11721317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dengue Fever: A Rare Cause Of Immune Thrombocytopenia.
    Ramírez-Fonseca T; Segarra-Torres A; Jaume-Anselmi F; Ramírez-Rivera J
    Bol Asoc Med P R; 2015; 107(2):51-3. PubMed ID: 26434084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Re: Recurrent immune thrombocytopenic purpura in children.
    Roganovic J; Letica-Crepulja M; Dordevic L
    Pediatr Hematol Oncol; 2008; 25(3):243-4. PubMed ID: 18432509
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy and safety of Privigen, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura.
    Robak T; Salama A; Kovaleva L; Vyhovska Y; Davies SV; Mazzucconi MG; Zenker O; Kiessling P;
    Hematology; 2009 Aug; 14(4):227-36. PubMed ID: 19635187
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous immunoglobulin and anti-RhD therapy in the management of immune thrombocytopenia.
    Cooper N
    Hematol Oncol Clin North Am; 2009 Dec; 23(6):1317-27. PubMed ID: 19932436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of a new intravenous immunoglobulin 10% formulation (octagam® 10%) in patients with immune thrombocytopenia.
    Robak T; Mainau C; Pyringer B; Chojnowski K; Warzocha K; Dmoszynska A; Straub J; Imbach P
    Hematology; 2010 Oct; 15(5):351-9. PubMed ID: 20863431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.